###begin article-title 0
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: CR ERM. Performed the experiments: CR. Analyzed the data: CR MZ ERM. Contributed reagents/materials/analysis tools: JL. Wrote the paper: CR ERM. Critically revised the manuscript: MZ JL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
The investigation of rare familial forms of kidney cancer has provided important insights into the biology of sporadic renal cell carcinoma (RCC). In particular, the identification of the von Hippel Lindau (VHL) familial cancer syndrome gene (VHL) provided the basis for the discovery that VHL is somatically inactivated in most sporadic clear cell RCC. Many cases of familial RCC do not have mutations in known RCC susceptibility genes and there is evidence that genetic modifiers may influence the risk of RCC in VHL disease patients. Hence we hypothesised that low-penetrance functional genetic variants in pathways related to the VHL protein (pVHL) function might (a) modify the phenotypic expression of VHL disease and/or (b) predispose to sporadic RCC.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 379 383 379 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 455 459 455 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
We tested this hypothesis for functional polymorphisms in CDH1 (rs16260), IGFBP3 (rs2854744), MMP1 (rs1799750), MMP3 (rs679620), STK15 (rs2273535) and VEGF (rs1570360). We observed that variants of MMP1 and MMP3 were significant modifiers of RCC risk (and risks of retinal angioma and cerebellar haemangioblastoma) in VHL disease patients. In addition, higher frequencies of the MMP1 rs1799750 2G allele (p = 0.017, OR 1.49, 95%CI 1.06-2.08) and the MMP1/MMP3 rs1799750/rs679620 2G/G haplotype (OR 1.45, 95%CI 1.01-2.10) were detected in sporadic RCC patients than in controls (n = 295).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 154 158 154 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
These findings (a) represent the first example of genetic modifiers of RCC risk in VHL disease, (b) replicate a previous report of an association between MMP1/MMP3 variants and sporadic RCC and (c) further implicate MMP1/MMP3-related pathways in the pathogenesis of familial and sporadic RCC.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 396 399 396 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 439 442 439 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Latif1">[1]</xref>
###xml 443 446 443 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Banks1">[4]</xref>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 555 558 555 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Kaelin1">[5]</xref>
###xml 618 621 618 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MET</italic>
###xml 623 631 623 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLCN, FH</italic>
###xml 636 640 636 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SDHB</italic>
###xml 683 686 683 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Pavlovich1">[6]</xref>
###xml 687 690 687 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Ricketts1">[7]</xref>
###xml 785 788 785 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Teh1">[8]</xref>
###xml 789 792 789 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Woodward1">[9]</xref>
###xml 877 881 877 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Webster1">[10]</xref>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Zatyka1">[11]</xref>
###xml 1228 1232 1228 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hammerschmied1">[13]</xref>
###xml 1233 1237 1233 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hirata1">[15]</xref>
###xml 1461 1465 1461 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 1467 1473 1467 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1475 1479 1475 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1481 1485 1481 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 1487 1492 1487 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1497 1501 1497 1501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1527 1531 1527 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 1553 1559 1553 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 1583 1587 1583 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1615 1619 1615 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 1699 1703 1699 1703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Li1">[16]</xref>
###xml 1704 1708 1704 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Prior1">[19]</xref>
###xml 1749 1754 1749 1754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1759 1763 1759 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 511 521 <span type="species:ncbi:111938">gatekeeper</span>
Familial renal cell carcinoma (RCC) accounts for 2-3% of all patients with RCC, but the investigation of rare familial forms of kidney cancer has provided important insights into the pathogenesis of non-familial RCC. Thus germline mutations in the von Hippel-Lindau (VHL) disease tumour suppressor gene (VHL) are the most common cause of familial renal cell carcinoma and somatic inactivation of VHL occurs in most sporadic clear cell RCC [1]-[4]. Hence the VHL tumour suppressor gene product (pVHL) has a key "gatekeeper" role in the pathogenesis of RCC [5]. Inherited mutations in a variety of other genes including MET, FLCN, FH and SDHB may also be associated with inherited RCC [6]-[7]. However, many cases of familial RCC do not have a mutation in known RCC susceptibility genes [8]-[9]. Furthermore, genetic modifier effects may influence the risk of RCC in VHL disease [10]-[11]. These observations suggest that unknown genetic factors contribute to the development of RCC. A variety of approaches have been employed in order to identify novel genetic causes of RCC including the mapping and characterisation of RCC-associated constitutional translocations (see 12 and references within) and genetic association studies [13]-[15]. We hypothesised that functional genetic variants in pathways related to pVHL function might modify the phenotypic expression of VHL disease and/or predispose to sporadic RCC. We tested this hypothesis for polymorphisms in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF. Polymorphic variants in CDH1 (rs16260 at c.-160), IGFBP3 (rs2854744 at c.-202), MMP1 (rs1799750 at c.-1607) and VEGF (rs1570360 at c.-1154) had previously been reported to alter promoter function [16]-[19]. In addition, missense substitutions in STK15 and MMP3 (rs2273535 (p.Phe31Ile) and rs679620 (p.K45E) respectively) were also analysed.
###end p 9
###begin title 10
Methods
###end title 10
###begin title 11
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Groups
###end title 11
###begin p 12
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 393 396 <span type="species:ncbi:9606">men</span>
###xml 467 472 <span type="species:ncbi:9606">women</span>
###xml 580 583 <span type="species:ncbi:9606">men</span>
###xml 798 810 <span type="species:ncbi:9606">participants</span>
219 patients and unaffected carriers with germline VHL mutations from 134 kindreds were analysed for the "VHL modifier analysis" study. We also analysed a cohort of 317 Polish sporadic RCC patients and 295 Polish normal controls that were matched to the patients by sex and approximate year of birth and were ascertained from the same region. The Polish sporadic RCC patients consisted of 226 men (mean age at diagnosis of RCC 60.7 years (range 26-89 years)) and 117 women (mean age at diagnosis of RCC 60.2 years (range 17-84 years)). The Polish normal controls consisted of 204 men (mean age 64 years (range 40-90 years)) and 117 (mean age 63.6 years (range 24-91 years)). All controls had a negative cancer family history. The study protocol was approved by the local Research Ethics bodies and participants gave informed consent.
###end p 12
###begin title 13
Molecular Genetic Studies
###end title 13
###begin p 14
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VHL</italic>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Ong1">[20]</xref>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 311 315 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 398 403 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 440 444 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 33 40 <span type="species:ncbi:9606">patient</span>
VHL mutation analysis in the VHL patient cohort was performed by direct sequencing and MLPA analysis and the mutation analysis results have been reported previously [20]. Genotyping of candidate functional polymorphisms in CDH1 (rs16260 promoter variant c.-C160A), IGFBP3 (rs2854744 promoter variant c.-C202A), MMP1 (rs1799750 promoter variant c.-1607 2G/1G), MMP3 (rs679620 c.A198G --> Lys45Glu), STK15 (rs2273535 c.T91A --> Phe31Ile) and VEGF (rs1570360 promoter variant c.-G1154). were performed by competitive allele specific PCR system (KASPar, KBiosciences). Details of primers and reaction conditions are available on request.
###end p 14
###begin title 15
Statistical analysis
###end title 15
###begin p 16
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 280 288 <span type="species:ncbi:9606">patients</span>
For the "VHL modifier analysis" study Kaplan-Meir survival curves were constructed and Cox regression analysis was performed to determine with the effect of different CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF alleles on age at onset of renal, retinal and cerebellar tumours in VHL patients.
###end p 16
###begin p 17
###xml 512 516 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wacholder1">[21]</xref>
###xml 1274 1278 1272 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1370 1374 1368 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1380 1384 1378 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Rutter1">[22]</xref>
###xml 1473 1477 1471 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hirata2">[23]</xref>
###xml 1478 1482 1476 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Ghilardi1">[26]</xref>
###xml 1556 1560 1554 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wacholder1">[21]</xref>
###xml 1566 1571 1564 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1661 1665 1659 1663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-EwartToland1">[27]</xref>
###xml 1734 1738 1732 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Dicioccio1">[28]</xref>
###xml 1739 1743 1737 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wang1">[31]</xref>
###xml 1860 1864 1858 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hammerschmied1">[13]</xref>
###xml 1997 2001 1995 1999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wacholder1">[21]</xref>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
For analysis of sporadic RCC patients and controls, deviation from Hardy Weinberg proportions for the genotypes of both markers and linkage disequilibrium between marker alleles was tested by chi2 tests. We calculated odds ratios (OR) and corresponding 95% confidence intervals (95%CI) using logistic regression for genotypic, allelic and haplotypic analyses. We estimated the false-positive report probability (FRFP) for statistically significant observations using the methodology described by Wacholder et al [21]. This method assumes that the prior probability that the association between a genetic variant and a disease is real is likely to be influenced by knowledge of the biological function of a gene and previous evidence that an association exists. The FRFP is calculated for a range of prior probabilities (50% to 0.1%). A prior probability of 50% might be appropriate when there is strong biological plausibility and consistent previous evidence for an association, whilst a prior probability of 0.1% would be appropriate when there is no biological or previous supporting evidence for an association. We selected the prior probabilities for the calculation of FRFP for our data according to the pre-existing evidence for likely association with RCC. Thus the MMP1 promoter polymorphism (rs1799750) has been shown previously to influence expression of the MMP1 gene [22] and has been reported previously to be associated with risk of RCC and other cancers in [23]-[26]. In the light of this prior probabilities of 25% (and 10%) were assigned [21]. The STK15 rs2273535 missense substitution has been reported previously to alter the STK15 function [27] and to be associated with numerous number of different cancer types [28]-[31]. However, in a previous study, no statistically significant association between rs2273535 and RCC risk was detected [13]. Hence more conservative prior probabilities (1%-10%) were selected for the calculation of FRFP. In accordance with Wacholder et al [21] a standard FRFP cut-off of less than 0.5 was selected with a cut-off of 0.2 being considered more stringent.
###end p 17
###begin p 18
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Niu1">[32]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Huber1">[33]</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-StataCorp1">[34]</xref>
A Bayesian statistical method for reconstructing uncertain haplotypes was applied by using the program PHASE [32] version 2.1. For allelic and haplotypic analyses, the Huber sandwich estimator of variance [33] have been calculated to take into account the clustering of two chromosomes within individuals. The most frequent haplotype (1G/G) was used as the reference haplotype. An omnibus likelihood ratio based test was performed to investigate whether the regression coefficient of at least one of the haplotypes in the model is not equal to zero. In the results the omnibus test showed no significance (p = 0.09). All statistical analyses were performed using Stata 9.0 [34].
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
VHL Modifier Analysis and variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF
###end title 20
###begin p 21
###xml 327 331 325 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 336 340 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 389 393 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 395 401 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 403 408 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 413 417 411 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 484 488 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 580 584 578 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 658 667 656 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006037-g001">Figure 1A</xref>
###xml 713 717 711 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 821 825 819 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 910 919 908 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006037-g002">Figure 2A</xref>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 782 790 <span type="species:ncbi:9606">patients</span>
Analysis of genotypes of candidate functional modifiers in 6 genes was performed using a Cox proportional hazard model analysis such that all the variables were entered into the regression model and then non-significant (P>0.1) variables removed. For RCC risk, the final model (overall chi2 = 11.9336 P = 0.0026) retained only MMP1 and MMP3 (P = 0.0291 and 0.0006731) and excluded SNPs in CDH1, IGFBP3, STK15 and VEGF as significant variables. VHL patients homozygous for the p.45Glu MMP3 allele (rs679620 c.198G) had an earlier onset of RCC than those homozygous for the p.45Lys MMP3 allele (rs679620 c.198A) and heterozygotes had an intermediate risk (see Figure 1A). Similarly, homozygotes for the "high-risk" MMP1 allele (rs1799750, c.-1607 2G) had an earlier onset of RCC than patients homozygous for the "low risk" MMP1 allele (rs1799750, c.-1607 1G), with heterozygotes having an intermediate risk (see Figure 2A).
###end p 21
###begin title 22
Effect of MMP3 rs679620 genotype on tumour risk in VHL disease.
###end title 22
###begin p 23
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Panel A: VHL patients homozygous for the p.45Glu MMP3 allele (rs679620 c.198G) had an earlier onset of RCC than those homozygous for the p.45Lys MMP3 allele (rs679620 c.198A) and heterozygotes had an intermediate risk. Similar associations were also found for onset of cerebellar haemangioblastoma and retinal angioma (see panels B and C respectively).
###end p 23
###begin title 24
Effect of MMP1 rs1799750 genotype on tumour risk in VHL disease.
###end title 24
###begin p 25
###xml 110 118 <span type="species:ncbi:9606">patients</span>
Panel A: Homozygotes for the "high-risk" MMP1 allele (rs1799750, c.-1607 2G) had an earlier onset of RCC than patients homozygous for the "low risk" MMP1 allele (rs1799750, c.-1607 1G), with heterozygotes having an intermediate risk. Similar associations were also found for onset of cerebellar haemangioblastoma and retinal angioma (see panels B and C respectively).
###end p 25
###begin p 26
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 391 395 389 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 412 416 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 562 566 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 583 587 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 656 660 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 672 678 668 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 692 697 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 714 718 710 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 790 794 786 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 954 958 950 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 991 1004 987 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006037-g002">Fig 2B and 2C</xref>
###xml 1038 1042 1034 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 1187 1191 1183 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 1221 1227 1217 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006037-g001">Fig 1B</xref>
###xml 1232 1238 1228 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006037-g001">Fig 1C</xref>
###xml 915 923 <span type="species:ncbi:9606">patients</span>
To determine if the observed modifier effects of MMP1 and MMP3 variants extended to other features of VHL disease, we repeated the Cox proportional hazard model analysis for age at diagnosis of retinal and cerebellar haemangioblastomas. This gave similar results, albeit less significant, to those for RCC. Thus for retinal angiomas the final model (overall chi2 = 7.04 P = 0.0296) retained MMP1 (rs1799750) and MMP3 (rs679620) (P = 0.012 and P = 0.041 respectively) and likewise, for cerebellar haemangioblastoma (overall model fit chi2 = 5.99 P = 0.0499) only MMP1 (rs1799750) and MMP3 (rs679620) were retained (P = 0.028 and P = 0.055 respectively) and CDH1 (rs16260), IGFBP3 (rs2854744), STK15 (rs2273535) and VEGF (rs1570360) were excluded. As for RCC, homozygotes for the "high-risk" MMP1 allele (rs1799750, c.-1607 2G) had an earlier age at diagnosis of retinal angioma and cerebellar haemangioblastoma than patients homozygous for the "low risk" MMP1 allele (rs1799750, c.-1607 1G) (Fig 2B and 2C) and homozygotes for the p.45Glu MMP3 allele (rs679620 c.198G) had earlier age at diagnosis of retinal angioma and cerebellar haemangioblastoma than those homozygous for the p.45Lys MMP3 allele (rs679620 c.198A (see Fig 1B and Fig 1C).
###end p 26
###begin title 27
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
RCC Association Study for variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF
###end title 27
###begin p 28
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 344 351 344 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006037-t001">Table 1</xref>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 257 265 <span type="species:ncbi:9606">patients</span>
317 RCC patients and 295 controls were analysed for six polymorphic variants in six candidate RCC susceptibility genes. All genotypes were in Hardy Weinberg equilibrium. Comparison of allele/genotype frequencies demonstrated significant differences between patients and controls for MMP1 rs1799750 and STK15 rs2273535 polymorphic variants (see Table 1).
###end p 28
###begin title 29
Genotyping data for sporadic RCC cases.
###end title 29
###begin p 30
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 278 285 278 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006037-t001">Table 1</xref>
###xml 352 356 352 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 514 521 514 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006037-t001">Table 1</xref>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wacholder1">[21]</xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
For the MMP1 rs1799750 polymorphic variant, the "high-risk" MMP1 allele (c.-1607 2G, that was associated with an earlier onset of RCC in VHL patients) was significantly increased in the Polish sporadic RCC patients compared to controls (p = 0.049 OR 1.25, 95%CI 1.003-1.55)(See Table 1). Additionally the homozygous genotype containing the "high-risk" MMP1 allele (rs1799750, c.-1607 2G) was significantly increased in the Polish sporadic RCC patients compared to controls (p = 0.030 OR 1.47, 95%CI 1.04-2.07)(See Table 1). According to the criteria of Wacholder et al [21], this result remained robust given the appropriate prior probabilities of 25% (FRFP = 0.139) and 10% (FRFP = 0.362).
###end p 30
###begin p 31
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 208 209 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
Although there were no significant differences between RCC patients and controls for MMP3 rs679620, there was strong evidence of linkage disequilibrium between MMP1 rs1799750 and MMP3 rs679620 (D' = 0.50, chi2 = 92.4, P<0.001). In the light of this haplotype analysis was undertaken. Comparison of haplotype risks to the reference haplotype rs1799750, c.-1607 1G/rs679620, 198G demonstrated a significant increased risk for rs1799750, c.-1607 2G/rs679620, 198G (OR 1.45, 95%CI 1.01-2.10) but not for rs1799750, c.-1607 1G/rs679620, 198A (OR 0.9, 95%CI 0.62-1.31) or rs1799750, c.-1607 2G/rs679620, 198A (OR 1.21, 95%CI 0.95-1.55) haplotypes. Thus the combination of the two alleles associated with increased tumour risk in VHL patients was also associated with the highest risk.
###end p 31
###begin p 32
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 240 247 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006037-t001">Table 1</xref>
###xml 168 176 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
For the STK15 rs2273535 polymorphic variant, the homozygous genotype containing the p.31Ile STK15 allele (c.91A) was significantly increased in the Polish sporadic RCC patients compared to controls (p = 0.044 OR 1.40, 95%CI 1.02-1.92) (See Table 1). The addition of the Polish familial RCC patients increased the significance (p = 0.027 OR 1.42, 95%CI 1.04-1.94). This result remained robust at a prior probability of 10% (FRFP = 0.365) but not with a prior probability of 1% (FRFP = 0.865).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 148 152 148 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Basset1">[35]</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-StetlerStevenson1">[37]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Rigel1">[38]</xref>
###xml 1054 1058 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-LpezOtn1">[39]</xref>
###xml 1074 1078 1074 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1135 1139 1135 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 1203 1207 1203 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Rutter1">[22]</xref>
###xml 1311 1315 1311 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Murray1">[40]</xref>
###xml 1316 1320 1316 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Ito1">[42]</xref>
###xml 1453 1457 1453 1457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Zhu1">[24]</xref>
###xml 1458 1462 1458 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Ghilardi1">[26]</xref>
###xml 1633 1637 1633 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hirata2">[23]</xref>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 1697 1705 <span type="species:ncbi:9606">patients</span>
Our findings suggest that functional SNPs in MMP1/MMP3 can influence susceptibility to RCC in familial (VHL disease) and sporadic patients and that MMP1 rs1799750 and MMP3 rs679620 genotypes can also influence the risk of retinal angioma and cerebellar haemangioblastoma in VHL disease. The ability to invade normal tissue and metastasise is a key feature of malignant neoplasms and the matrix metalloproteinase family of zinc-dependent enzymes (MMPs) have a key role in degrading the extracellular matrix and facilitating tissue invasion by cancer cells. In addition, MMPs may regulate availability of growth factors and enhance angiogenesis [35]-[37]. Matrix metalloproteinase 1 (MMP1) has a specific ability to degrade type-I collagen (the most abundant substrate in the tumour surrounding stroma) and has been implicated in tumour invasion and metastasis [38], whereas MMP3 degrades a broader range of substrates (e.g. fibronectin, laminin, collagens III, IV, IX, and X, and cartilage proteoglycans), and may also affect the expression of other MMPs [39]. The rs1799750 MMP1 1G/2G promoter polymorphism has been shown to influence MMP1 transcription in both normal fibroblasts and in melanoma cells [22]. An inverse correlation between MMP1 expression and cancer prognosis has been reported in many cancers [40]-[42] and the rs1799750 variant has been linked with an increased risk of developing lung, ovarian, colorectal, and head and neck cancers [24]-[26]. In addition, Hirata et al (2003) reported an increased frequency of the rs1799750 2G variant in RCC cases (n = 119) from Japan compared to population controls (n = 210) [23]. We have replicated this finding in a larger cohort of RCC patients from a different ethnic group.
###end p 34
###begin p 35
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Zhang1">[43]</xref>
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Krippl1">[45]</xref>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 336 339 336 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 560 564 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 771 775 771 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 789 793 789 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 980 988 <span type="species:ncbi:9606">patients</span>
The rs679620 A MMP3 p.K45E polymorphism in the matrix metalloproteinase 3 (stromelysin-I) gene has been associated previously with differences in MMP3 activity and has been linked to cancer susceptibility in some studies [43]-[45]. Association studies of MMP1 and MMP3 SNPs are complicated by the colocation of these two genes within a MMP gene cluster at 11q22.3 and we detected evidence of strong linkage disequilibrium between rs1799750 and rs679620. A previous study demonstrated an association between a rs1799750 and rs679620 haplotype consisting of the MMP1 1G/2G polymorphism and the MMP3 Glu45Lys polymorphism. Hence we investigated both variants separately and as a combined haplotype. This demonstrated that the strongest link with RCC was associated with the MMP1 rs1799750 2G/MMP3 rs679620 G haplotype. Again this is consistent with the findings of Hirata et al (2004) who reported that the frequency of the same allelic haplotype was significantly higher in the RCC patients of Japanese descent than in the controls (crude OR = 1.95, 95%CI = 1.31-2.91).
###end p 35
###begin p 36
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH1</italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hammerschmied1">[13]</xref>
###xml 748 753 748 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1030 1034 1030 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Zhou1">[46]</xref>
###xml 1051 1056 1051 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1144 1148 1144 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-EwartToland1">[27]</xref>
###xml 1287 1291 1287 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Dicioccio1">[28]</xref>
###xml 1292 1296 1292 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wang1">[31]</xref>
###xml 1328 1332 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hammerschmied1">[13]</xref>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
###xml 484 492 <span type="species:ncbi:9606">patients</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
###xml 1418 1425 <span type="species:ncbi:9606">patient</span>
We did not find any evidence that the tested genetic variants in CDH1 (rs16260), IGFBP3 (rs2854744), VEGF (rs1570360) and STK15 (rs2273535) influenced risk of RCC in VHL disease patients. Unlike MMP1 and MMP3, none of these variants has previously been associated with RCC risk in sporadic patients [13]. Thus there would appear to be a good correlation between variants that can modify RCC risk in VHL and those that have been reported to be associated with RCC risk in sporadic RCC patients. However, there are two caveats to this observation. Firstly it is possible that that these variants might be demonstrated an effect in larger studies. Secondly, we detected a statistically significant association between a genetic variant (rs2273535) in STK15 and RCC in sporadic patients. STK15 (Aurora-A) is a serine/threonine kinase essential for chromosome segregation and cytokinesis. Overexpression of STK15 is common in many cancers and is associated with centrosome amplification, chromosome instability and cell transformation [46]. Previously the STK15 (rs2273535, p.Phe31Ile) variant was found to alter the potency of STK15 transformation [27] and was reported to be associated with cancer risk in a number of cancer types including ovarian, colorectal, breast, oesophagus and lung [28]-[31]. Although, Hammerschmeid et al [13] did not detect a significant association between the p.Phe31Ile variant and RCC, the patient and control study groups (n = 156 and n = 158 respectively) were less than half as many as those analysed by us and so further analysis of a larger groups is indicated.
###end p 36
###begin p 37
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Wacholder1">[21]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Hung1">[47]</xref>
###xml 689 694 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
We estimated the false-positive reporting probability (FPRP) for our results by incorporating a range of prior probabilities that specific polymorphisms are associated with RCC risk [21], [47]. The association between the MMP1 genotype and RCC risk was extremely robust with a prior probability of 25% (FRFP = 0.139) (and remained robust if the prior probability was reduced to 10%). Given that the pre-existing evidence for an association between the STK15 p.Phe31Ile variant and RCC was less secure a lower prior probability (10%) was selected. Whilst the FRFP was still in favour of a real association (FRFP = 0.365) at this prior probability, it should be emphasised that the putative STK15 association should be confirmed in larger cohorts.
###end p 37
###begin p 38
###xml 238 242 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Webster1">[10]</xref>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCND1</italic>
###xml 444 448 444 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Zatyka1">[11]</xref>
###xml 494 498 494 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 644 648 644 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1</italic>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP3</italic>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Webster1">[10]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Koochekpour1">[48]</xref>
###xml 1477 1486 1465 1474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP1/MMP3</italic>
###xml 1562 1566 1550 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Katayama1">[49]</xref>
###xml 1567 1571 1555 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006037-Roe1">[50]</xref>
###xml 1631 1636 1619 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 1805 1810 1793 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STK15</italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 2246 2254 <span type="species:ncbi:9606">patients</span>
Previously, we reported that the phenotypic expression of VHL disease is influenced by modifier effects and that patients with more severe retinal angiomatosis also had increased age-related risks of cerebellar haemangioblastomas and RCC [10]. Subsequently, we reported that a functional variant in the VHL target gene CCND1 influenced risk of retinal angiomas and central nervous system hemangioblastomas (but not RCC) in VHL disease patients [11]. Hence the finding of an association between MMP1 and MMP3 genotypes and RCC risk represents the first examples of genetic modifiers of RCC risk in VHL disease. In addition, the observation that MMP1 and MMP3 genotypes also appeared to influence retinal angioma and cerebellar haemangioblastoma risks is consistent with our previous report suggesting shared genetic modifiers of retinal angiomatosis, cerebellar haemangioblastomas and RCC risks in VHL disease [10]. Previously, pVHL was reported to downregulate metalloproteinases, such as MMP1, and upregulate MMP inhibitors (TIMPs) [48], so it is not unreasonable to suggset that genetic variants in MMP/TIMP pathways might influence tumourigenesis in VHL disease. In addition, as somatic VHL inactivation occurs in most clear cell RCC, and this histopathology accounts for approximately75% of all sporadic RCC, it is not unexpected that genetic modifiers of VHL disease RCC risk, might also function as low penetrance RCC susceptibility alleles (e.g. the association between MMP1/MMP3 hapolotypes and RCC). Both STK15 and pVHL have been linked to p53 function [49]-[50], but although we found evidence for an association between STK15 rs2273535 31Ile genotype and RCC susceptibility, there was no apparent evidence of modifier effects in VHL disease. Further studies are required to confirm the role of STK15 variation in RCC susceptibility but it could be that the influence of germline STK15 variants is predominantly on a VHL-independent pathway of renal tumourigenesis. Our findings suggest that functional genetic variants in VHL-related pathways should be further evaluated as candidate genetic modifiers in VHL disease and as RCC susceptibility alleles. The identification of common variants associated with RCC risk in VHL and sporadic patients could provide further insights into RCC biology and highlight candidate familial RCC genes suitable for resequencing studies to detect rare high penetrance mutations.
###end p 38
###begin title 39
References
###end title 39
###begin article-title 40
Identification of the von Hippel-Lindau disease tumor suppressor gene.
###end article-title 40
###begin article-title 41
Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.
###end article-title 41
###begin article-title 42
Mutations of the VHL tumour suppressor gene in renal carcinoma.
###end article-title 42
###begin article-title 43
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
###end article-title 43
###begin article-title 44
The VHL tumour-suppressor gene paradigm.
###end article-title 44
###begin article-title 45
Searching for the hereditary causes of renal-cell carcinoma.
###end article-title 45
###begin article-title 46
Germline SDHB mutations and familial renal cell carcinoma.
###end article-title 46
###begin article-title 47
Familial non-VHL non-papillary clear-cell renal cancer.
###end article-title 47
###begin article-title 48
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
###end article-title 48
###begin article-title 49
An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects.
###end article-title 49
###begin article-title 50
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
###end article-title 50
###begin article-title 51
Characterization of a 3;6 translocation associated with renal cell carcinoma.
###end article-title 51
###begin article-title 52
Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma.
###end article-title 52
###begin article-title 53
Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype.
###end article-title 53
###begin article-title 54
Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma.
###end article-title 54
###begin article-title 55
A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities.
###end article-title 55
###begin article-title 56
Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators.
###end article-title 56
###begin article-title 57
The use of allelic expression differences to ascertain functional polymorphisms acting in cis: analysis of MMP1 transcripts in normal lung tissue.
###end article-title 57
###begin article-title 58
DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption.
###end article-title 58
###begin article-title 59
Genotype-phenotype correlations in von Hippel-Lindau disease.
###end article-title 59
###begin article-title 60
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.
###end article-title 60
###begin article-title 61
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription.
###end article-title 61
###begin article-title 62
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma.
###end article-title 62
###begin article-title 63
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility.
###end article-title 63
###begin article-title 64
Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region.
###end article-title 64
###begin article-title 65
Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness.
###end article-title 65
###begin article-title 66
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
###xml 98 103 <span type="species:ncbi:9606">human</span>
Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human.
###end article-title 66
###begin article-title 67
STK15 polymorphisms and association with risk of invasive ovarian cancer.
###end article-title 67
###begin article-title 68
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types.
###end article-title 68
###begin article-title 69
Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk.
###end article-title 69
###begin article-title 70
Genetic variants in cell cycle control pathway confer susceptibility to lung cancer.
###end article-title 70
###begin article-title 71
Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms.
###end article-title 71
###begin article-title 72
"The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions."
###end article-title 72
###begin article-title 73
Statistical Software: Release 9.0.
###end article-title 73
###begin article-title 74
###xml 50 55 <span type="species:ncbi:9606">human</span>
Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications.
###end article-title 74
###begin article-title 75
Matrix metalloproteinases: biologic activity and clinical implications.
###end article-title 75
###begin article-title 76
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.
###end article-title 76
###begin article-title 77
Factors influencing survival in melanoma.
###end article-title 77
###begin article-title 78
Emerging roles of proteases in tumour suppression.
###end article-title 78
###begin article-title 79
Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer.
###end article-title 79
###begin article-title 80
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer.
###end article-title 80
###begin article-title 81
###xml 27 32 <span type="species:ncbi:9606">human</span>
Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor.
###end article-title 81
###begin article-title 82
The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma.
###end article-title 82
###begin article-title 83
Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma.
###end article-title 83
###begin article-title 84
The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer.
###end article-title 84
###begin article-title 85
Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.
###end article-title 85
###begin article-title 86
Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study.
###end article-title 86
###begin article-title 87
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells.
###end article-title 87
###begin article-title 88
Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization andinhibition of p53.
###end article-title 88
###begin article-title 89
p53 stabilization and transactivation by a von Hippel-Lindau protein.
###end article-title 89
###begin p 90
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 90
###begin p 91
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: We thank Cancer Research UK for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 91

